Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

Date: May 20, 2019 Issue #:  1572Summary:  The FDA has approved omadacycline (Nuzyra– Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Antibacterials Avelox Bactrim Cefadroxil Ceftriaxone Cephalexin Clindamycin Dicloxacillin Doxycycline Haemophilus influenzae Levofloxacin Linezolid Moxifloxacin Mycoplasma pneumoniae Nuzyra omadacycline skin and skin struct Source Type: research